Hepatitis C virus (HCV) infection is the leading cause of liver disease in hemophilia patients. In those with human immunodeficiency virus (HIV)/HCV coinfection, the rate of liver disease progression is greater than in HCV monoinfected individuals. Despite antiretroviral therapy, which slows HCV liver disease progression, some require transplantation. Whether transplant outcomes are worse in hemophilic (H) rather than nonhemophilic (NH) candidates is unknown. In order to determine rates and predictors of pretransplant and posttransplant survival, we conducted a retrospective observational study using United Network for Organ Sharing national transplant registry data, comparing HCV1 H and NH candidates. We identified 2502 HCV1 liver transplant candidates from 8 US university-based transplant centers, between January 1, 2004 to December 31, 2010, including 144 HIV1 (6%) and 2358 HIV-; 36 H (1%) and 2466 NH; 1213 (48%) transplanted and 1289 not transplanted. Other than male predominance and younger age, each were P < 0.001. Baseline data were comparable between H and NH. In univariate analysis, 90-day pretransplant mortality was associated with higher baseline Model for End-Stage Liver Disease (MELD; hazard ratio [HR] 5 1.15; P < 0.001), lower baseline platelet count (HR 5 0.9 per 25,000/mL; P 5 0.04), and having HIV/HCV1 hemophilia (P 5 0.003). In multivariate analysis, pretransplant mortality was associated with higher MELD (P < 0.001) and was significantly greater in HIV1 than HIV-groups (P 5 0.001). However, it did not differ between HIV1 H and NH (HR 5 1.7; P 5 0.36). Among HIV/HCV1, posttransplant mortality was similar between H and NH, despite lower CD4 in H (P 5 0.04). In conclusion, this observational study confirms that hemophilia per se does not have a specific influence on transplant outcomes and that HIV infection increases the risk of mortality in both H and NH patients.
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Hepatitis C virus (HCV) is the major cause of chronic liver disease and mortality among adults with hemophilia.
(1,2) Approximately 90% of hemophilic (H) men exposed to HCV through clotting factor concentrates prior to the acquired immune deficiency syndrome era became infected with HCV, (3, 4) and up to 80% of HCV-infected H men were coinfected with human immunodeficiency virus (HIV).
(1,3) HIV accelerates HCV liver disease progression, (1, 2, (5) (6) (7) and although combination antiretroviral therapy improves HIV survival, (8) slows HCV progression to end-stage liver disease (ESLD), and improves ESLD-free survival, (9) (10) (11) some ultimately require liver transplantation (LT). After 25 years of HIV/HCV coinfection, approximately one-fourth have biopsy-proven fibrosis (2) and 5%-10% have progressed to ESLD, (1, 2) consistent with findings in other risk groups. (6, 11) Abbreviations: BMI, body mass index; CI, confidence interval; DAA, direct-acting antiviral; ESLD, end-stage liver disease; H, hemophilic; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HIV-TR, human immunodeficiency virus solid organ transplant; HOTS, Hemophilia Liver Transplantation Observational Study; HR, hazard ratio; ICD, International Classification of Diseases; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; NH, nonhemophilic; PCR, polymerase chain reaction; UNOS, United Network for Organ Sharing.
In contrast to other risk groups, however, individuals with hemophilia have the following concerns:
1. Longer duration HCV infection, with acquisition via clotting factor typically in the first year of life. (12) 2. Greater bleeding risk and occurrence of bleeding complications (1, 2, 7, 13) due to factor VIII (or IX) deficiency in the setting of thrombocytopenia and prolonged international normalized ratio in ESLD.
These risks are important because duration of HCV infection has been shown to be a significant predictor of liver disease progression. (1, 6, 14) Moreover, increased bleeding frequency, including gastrointestinal bleeding, (7, 13) increases posttransplant mortality. (7, 15, 16) Several studies have shown that posttransplant survival is shorter in HIV/HCV coinfected than HCV monoinfected candidates and not different between HIV/HCV H and nonhemophilic (NH) recipients. (7, 17, 18) Pretransplant survival in HIV/HCV coinfected candidates with hemophilia is shorter than in NH candidates. (19) Because the latter studies were small, analysis for predictors of pretransplant survival was limited. Thus, we sought to evaluate pretransplant outcomes using a larger national database of US transplant candidates, the United Network for Organ Sharing (UNOS), collaborating with the 8 transplant centers of the original human immunodeficiency virus solid organ transplant (HIV-TR) study with hemophilia transplant candidates. (18) Patients and Methods
PATIENTS
We identified 2817 patients in the UNOS database (20) by the following criteria: all HCV1 LT candidates listed or transplanted at 1 of the 8 centers, participating in the HIV-TR study (18) between January 1, 2004 and December 31, 2010, and who did not have hepatocellular carcinoma (HCC) or a Model for End-Stage Liver Disease (MELD)/Pediatric EndStage Liver Disease exclusion anytime on the waiting list. The study was reviewed and received approval by each individual institutional review board. HCV1 patients were identified as any candidate or corresponding recipient who had a diagnosis for transplant related to hepatitis C or who at the time of transplantation was HCV seropositive. A 7-item case report form was completed on each patient by respective transplant centers. UNOS data sets were provided to each of the 8 centers to identify each patient by the following characteristics: The latter 4 were labs at listing and at transplantation. Data were entered by participating sites on the Emmes online data entry system, cleaned, and verified. After eliminating 315 cases for other HCC cases identified in the UNOS data sets (n 5 287), missing records, missing HIV status, missing hemophilia status, or hemophilia C, a total of 2502 LT candidates remained for analysis.
STATISTICAL ANALYSIS
We performed univariate proportional hazards models for pretransplant mortality within 90 days of listing, which included group and baseline factors ( Table 1) .
Variables with P < 0.1 from the univariate models were included in an initial multivariate model. KaplanMeier time-to-event curves were constructed for LT candidates, including time to death, time to transplant, and time to a MELD score of 25; and for LT recipients, including time to death and time-to-graft loss. Statistical analysis was carried out using SAS version 9.3 (SAS Institute, Cary, NC). NOTE: Data are given as n or n (%) unless otherwise noted. NOTE: Data are given as n (%).
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Results
We identified 2502 HCV1 LT candidates, including 144 (6%) with HIV infection and 36 (1%) with hemophilia, and 1213 (48%) transplant recipients (Table 1) . Baseline data among groups were comparable, although, as expected, the proportion of males was significantly higher in those with hemophilia, as compared with NH groups, and age was significantly lower in the HIV1 hemophilia group, as compared with the other 3 groups (P < 0.001). Among HIV1 groups, body mass index (BMI) was lower than in the HIV-groups (P < 0.001), and log HCV RNA was higher in the HIV1 NH group than in the other 3 groups (P < 0.001).
Clinical outcomes are shown in Table 2 . A total of 1289 pretransplant candidates were not transplanted (18 H, 1271 NH); 771 remained alive or were removed from listing before transplant (13 H, 758 NH); and 518 died before transplant (5 H, 513 N). The most common causes of pretransplant death included multiorgan failure in 113 (22%; 1 H, 112 NH); sepsis or infection in 86 (17%; 0 H, 86 NH); other causes in 157 (30%; 3 H, 154 NH); or unknown causes in 162 (31%; 1 H, 161 NH).
Among the transplant candidates, the overall pretransplant patient survival at 90 days and 6 months from listing did not differ significantly between H and NH groups (Table 3 ). In the first 90 days after listing, time-to-event curves for death and elevated MELD 25 were significantly different between groups, log-rank (P < 0.001 and 0.02, respectively). Time-to-event curves for transplant within the first 90 days were not significantly different between the 4 groups (P 5 0.26; Figs. 1 and 2) .
In univariate proportional hazards models, pretransplant mortality within 90 days of listing was associated with higher baseline MELD (hazard ratio [HR] 5 1.15; P < 0.001) and lower baseline platelet count (HR 5 0.9 per 25,000/mL; P 5 0.04; Table 4 ). Compared with the HIV-NH group, HIV1 H candidates (HR 5 5.1; P 5 0.001) and HIV1 NH candidates (HR 5 1.8; P 5 0.04) had a significantly higher hazard of pretransplant mortality, marginally worse in HIV1 H candidates than in HIV1 NH candidates (HR 5 2.8; P 5 0.08). Factors with P < 0.1 from the univariate model were included in an initial multivariate model: after dropping platelet count (<100,000 versus 100,000; P 5 0.67), the model was refit. In the final multivariate model, higher MELD score was significantly associated with pretransplant mortality (P < 0.001), and the 2 HIV1 groups combined had significantly worse pretransplant survival within 90 days of listing than the 2 HIV-groups combined (P 5 0.001). The hazard of pretransplant mortality, however, was not significantly worse in HIV1 H than HIV1 NH (HR 5 1.7; P 5 0.36).
Clinical outcomes among transplant recipients are shown in Table 2 . Of 2502 transplant candidates, 1213 underwent LT (18 H and 1195 NH), of whom 943 remain alive (12 H and 931 NH); and 270 died after transplant (6 H and 264 NH). The most common causes of posttransplant death were multiorgan failure in 40 (15%; 0 H, 40 NH); sepsis or infection in 54 (20%; 3 H, 51 NH); other causes in 148 (55%; 3 H, 145 NH); or unknown cause in 28 (10%; 0 H, 28 NH). Among the 1213 LT recipients, posttransplant mortality at 1 year and 3 years after transplantation did not differ significantly between H and NH groups (combined log-rank, P 5 0.31), and similarly, posttransplant graft survival did not differ between H and NH groups (combined log-rank, P 5 0.62; Table 5 ). In the first 3 years after transplant, Kaplan-Meier time-to-death was significantly different between HIV1 and HIV-groups (combined log-rank, P 5 0.002; as was time-to-graft loss, P 5 0.002; Fig.  2 ). Time to death was significantly different only between HIV1 NH and HIV-NH groups (log-rank, P 5 0.01), but not between HIV1 H and HIV-H groups (P 5 0.40), likely due to small hemophilia sample size. Similarly, graft survival was significantly different between HIV1 NH and HIV-NH groups (log-rank, P 5 0.003) but not between HIV1 H and HIV-H groups (P 5 0.40). 
Discussion
This retrospective observational study was designed to determine the predictors of poor pretransplant survival in H men, using UNOS national transplant registry data from 8 US transplant centers. Given the importance of age (14) and bleeding risk (15, 16) in HCV outcome and in ESLD thrombocytopenia (1, 2, 7, 13) and the recognized longer duration of HCV infection (1, 2, 17) in those with hemophilia than in NH transplant candidates, we identified a HR of 2.0 for pretransplant mortality, comparing HIV1 H and NH transplant candidates. Although the increased risk was large, it was not significant and could be the result of the small number of HIV/HCV1 transplant candidates. Our previous solid organ transplant HIV-TR substudy (19) did identify significantly poorer pretransplant survival in hemophilia, but because it was a small pilot study, we sought to confirm the findings in a larger study. Using the large UNOS database, we hypothesized that MELD score was not as good a predictor of pretransplant mortality in H than NH candidates, and that hemophilia status itself shortens pretransplant survival because of longer HCV duration and greater bleeding in the setting of ESLD thrombocytopenia.
The Hemophilia Liver Transplantation Observational Study (HOTS) study also found that survival in HIV1 candidates was poorer than in HIV-candidates, which differs from the findings of the larger HIV-TR study, (18) which is likely related to differences between the studies. First, the HOTS analysis was of 4 comparison groups, including hemophilia status, whereas the HIV-TR study was only a 2-comparison group analysis, HIV1 versus HIV-. Second, although our study focused on HCV1, non-HCC candidates, the HIV-TR study included HCV-and HCC candidates: it is well-known that pretransplant outcomes are worse in HCV1, non-HCC candidates who have HIV coinfection. However, both studies showed increased mortality in HIV1 pretransplant candidates, which, although not significant in the previous HIV-TR study, was significant in this study, which is likely related to the small number of H transplant candidates. The greater risk of pretransplant death in HIV1 than HIV-patients was independent of the MELD score, as indicated in multivariate analysis. Thus, exception MELD points might be given to HIV1 candidates to mitigate this disadvantage.
The current study has several limitations. The first is the small sample size, especially the small number of hemophilia candidates, some of whom may have been One potential approach to address these limitations is by implementation of ICD classification codes for hemophilia, hemophilia A, 286.0 (D66), hemophilia B, 286.1 (D67), in the UNOS transplant registry. Although hemophilia is a rare disease characterized by fewer than 1 in 50,000 male births, it is of note that H men who develop ESLD account for 10% of all LTs performed in HIV/HCV coinfected individuals in the United States. (1, 17, 18) In addition, in H patients with ESLD who develop bleeding complications, eg, gastrointestinal tract bleeding, mortality may increase while awaiting transplantation, (7, 15, 16) confirming the importance of early, aggressive factor replacement. Third, as new DAA agents are incorporated into pretransplant and posttransplant management, the proportion requiring transplant should be monitored, as well as outcome among those who undergo transplant. Increasingly, evidence indicates DAAs not only provide excellent control of chronic HCV infection but also improve posttransplant survival and pretransplant outcomes, with some candidates no longer requiring transplantation. (21) In summary, this observational study confirms that hemophilia per se does not have significant influence on pretransplant and posttransplant outcomes and that HIV infection increases mortality in both H and NH patients.
